<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39331188</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1437-2320</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Neurosurgical review</Title><ISOAbbreviation>Neurosurg Rev</ISOAbbreviation></Journal><ArticleTitle>Epidemiology and risk factors for adult gliomas died by respiratory diseases during the COVID-19 pandemic: a population-based study.</ArticleTitle><Pagination><StartPage>700</StartPage><MedlinePgn>700</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10143-024-02943-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The research on epidemiology of gliomas died of respiratory diseases (RDs) is very scarce. The study aimed to explore the epidemiology and risk factors for adult gliomas death from respiratory diseases during the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adult gliomas patients (age ≥ 18 years) diagnosed between 2020 and 2021 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching analysis was used to reduce confounding bias between gliomas died of respiratory diseases and died of gliomas directly. The Cox proportional hazards regression model and Kaplan-Meier (K-M) survival curves were used for survival analyses in the matched groups. Logistic regression analyses were conducted to identify risk factors for dying of respiratory diseases in the entire population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 9315 eligible adult gliomas enrolled in the study, 39.4% died from gliomas, 1.0% from respiratory diseases, and 61.4% survived. Gliomas who died from respiratory diseases had a trend towards a higher risk of death (HR = 1.35, P = 0.031). Surgery did not increase the all-cause mortality risk (HR = 0.86, P = 0.327). The K-M survival curves suggested a worse prognosis for dying from respiratory diseases. Those who died from RDs had a shortened median survival (median 3 months) compared with those who died from gliomas directly (median 5 months). Multivariable logistic regression models indicated that those aged ≥ 65 years, with median household income &lt; 75,000$/year, and not receiving surgery had a higher risk of dying from RDs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">RDs have become a crucial cause of death for gliomas. Those with advanced age and lower median household income have a higher risk of dying from respiratory diseases. Surgical treatment has been found to be safe for glioma patients and has been shown to reduce the risk of glioma patients dying from respiratory diseases. The study provides valuable insights for the perioperative management of gliomas patients in the post-pandemic era.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Han</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Continuing Education, Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, The First Affliated Hospital of Bengbu Medical University, Bengbu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, The First Affliated Hospital of Bengbu Medical University, Bengbu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Yesen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, The First Affliated Hospital of Bengbu Medical University, Bengbu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jiwei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, The First Affliated Hospital of Bengbu Medical University, Bengbu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zhiquan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Continuing Education, Anhui Medical University, Hefei, China. bbjiangzhq@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, The First Affliated Hospital of Bengbu Medical University, Bengbu, China. bbjiangzhq@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Neurosurg Rev</MedlineTA><NlmUniqueID>7908181</NlmUniqueID><ISSNLinking>0344-5607</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005910" MajorTopicYN="Y">Glioma</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018426" MajorTopicYN="N">SEER Program</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012140" MajorTopicYN="N">Respiratory Tract Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult gliomas</Keyword><Keyword MajorTopicYN="N">Respiratory diseases</Keyword><Keyword MajorTopicYN="N">Risk factor</Keyword><Keyword MajorTopicYN="N">SEER</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331188</ArticleId><ArticleId IdType="doi">10.1007/s10143-024-02943-7</ArticleId><ArticleId IdType="pii">10.1007/s10143-024-02943-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C et al (2023) CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2016–2020. Neurooncology 25:iv1–iv99</Citation></Reference><Reference><Citation>Yang C, Tan Y, Li S, Zhou J, Wang Q, Wang Y et al (2019) Genomic landscapes by multiregion sequencing combined with circulation tumor DNA detection contribute to molecular diagnosis in glioblastomas. Aging 11:11224</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.102526</ArticleId><ArticleId IdType="pubmed">31822636</ArticleId><ArticleId IdType="pmc">6932900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoggarth AR, Muthukumar S, Thomas SM, Crowley J, Kiser J, Witcher MR (2024) Clinical theranostics in recurrent gliomas: a review. Cancers 16:1715</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers16091715</ArticleId><ArticleId IdType="pubmed">38730666</ArticleId><ArticleId IdType="pmc">11083317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D, Wang M, Chen Y, Gong J, Chen L, Shi X et al (2021) Trends in Intracranial Glioma incidence and mortality in the United States, 1975–2018. Front Oncol 11:748061</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.748061</ArticleId><ArticleId IdType="pubmed">34790574</ArticleId><ArticleId IdType="pmc">8591029</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Chen H, Tang T (2023) Risk of death from Alzheimer’s Disease Associated with Brain Tumor, Glioma, and Glioblastoma. J Alzheimers Dis. :1–9</Citation></Reference><Reference><Citation>Wang X, Li X, Wu Y, Hong J, Chai D, Zhang M (2023) Risk of cardiac-related death in astrocytoma patients treated with chemotherapy: a competing risk analysis using the SEER database. Front Cardiovasc Med 10:996354</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.996354</ArticleId><ArticleId IdType="pubmed">37180801</ArticleId><ArticleId IdType="pmc">10167282</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumi T, Koshino Y, Michimata H, Nagayama D, Watanabe H, Yamada Y et al (2022) Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report. Translational Lung Cancer Res 11:1973</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tlcr-22-388</ArticleId></ArticleIdList></Reference><Reference><Citation>Che W, Ma W, Lyu J, Wang X (2021) Socioeconomic status and adult gliomas mortality risk: an observational study based on SEER Data. World Neurosurg 155:e131–e41</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2021.08.034</ArticleId><ArticleId IdType="pubmed">34403798</ArticleId></ArticleIdList></Reference><Reference><Citation>Che W-Q, Li Y-J, Tsang C-K, Wang Y-J, Chen Z, Wang X-Y et al (2023) How to use the Surveillance, Epidemiology, and end results (SEER) data: research design and methodology. Military Med Res 10:50</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-023-00488-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohile NA, Blakeley JO, Gatson NTN, Hottinger AF, Lassman AB, Ney DE et al (2020) Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. Neurooncology 22:912–917</Citation></Reference><Reference><Citation>Pellerino A, Caccese M, Padovan M, Cerretti G, Lombardi G (2022) Epidemiology, risk factors, and prognostic factors of gliomas. Clin Translational Imaging 10:467–475</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40336-022-00489-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A et al (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma outcomes Project. J Neurosurg 99:467–473</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.2003.99.3.0467</ArticleId><ArticleId IdType="pubmed">12959431</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Guan W, Chen R, Wang W, Li J, Xu K et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21:335–337</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30096-6</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId><ArticleId IdType="pmc">7159000</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323:1775–1776</Citation><ArticleIdList><ArticleId IdType="pubmed">32203977</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogado J, Obispo B, Pangua C, Serrano-Montero G, Marino AM, Lopez-Alfonso A et al (2020) 1685P is cancer what determines COVID-19 oncological patient’s outcome or are other external factors involved? Experience in a hospital in Madrid, Spain. Ann Oncol 31:S997</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.08.1749</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhtar Z, Sharma S, Elbatran AI, Leung LWM, Kontogiannis C, Spartalis M et al (2022) Medium-term outcomes in COVID-19. J Clin Med 11:2033</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11072033</ArticleId><ArticleId IdType="pubmed">35407640</ArticleId><ArticleId IdType="pmc">9000210</ArticleId></ArticleIdList></Reference><Reference><Citation>Park C, Razjouyan J, Hanania NA, Helmer DA, Naik AD, Lynch KE et al (2022) Elevated risk of chronic respiratory conditions within 60 days of COVID-19 hospitalization in Veterans. MDPI, p 300</Citation></Reference><Reference><Citation>Gül U, Altuntaş D, Efe E (2022) A year and a half later: clinical experiences of intern nursing students in the COVID-19 pandemic: a constructivist grounded theory. Nurse Educ Pract 63:103381</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nepr.2022.103381</ArticleId><ArticleId IdType="pubmed">35717729</ArticleId><ArticleId IdType="pmc">9194461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartsonaki C, Baillie JK, Barrio NG, Baruch J, Beane A, Blumberg L et al (2023) Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19. Int J Epidemiol 52:355–376</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyad012</ArticleId><ArticleId IdType="pubmed">36850054</ArticleId><ArticleId IdType="pmc">10114094</ArticleId></ArticleIdList></Reference><Reference><Citation>Starke KR, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A (2021) The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Global Health 6:e006434</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-006434</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Bartels CM, Rovin RA, Lamb LE, Kind AJH, Nerenz DR (2021) Race, ethnicity, neighborhood characteristics, and in-hospital coronavirus disease-2019 mortality. Med Care 59:888–892</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000001624</ArticleId><ArticleId IdType="pubmed">34334737</ArticleId><ArticleId IdType="pmc">8446301</ArticleId></ArticleIdList></Reference><Reference><Citation>Veiga VC, Cavalcanti AB (2023) Age, host response, and mortality in COVID-19. Eur Respiratory Soc</Citation></Reference><Reference><Citation>Mirosevic S, Jo B, Kraemer HC, Ershadi M, Neri E, Spiegel D (2019) Not just another meta-analysis: sources of heterogeneity in psychosocial treatment effect on cancer survival. Cancer Med 8:363–373</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.1895</ArticleId><ArticleId IdType="pubmed">30600642</ArticleId><ArticleId IdType="pmc">6346264</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K-X, Yuan W-J, Huang C-H, Xiao L, Xiao R-S, Zeng P-W et al (2022) Socioeconomic deprivation and survival outcomes in patients with colorectal cancer. Am J Cancer Res 12:829</Citation><ArticleIdList><ArticleId IdType="pubmed">35261805</ArticleId><ArticleId IdType="pmc">8899994</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC et al (2020) Colorectal cancer statistics, 2020. Cancer J Clin 70:145–164</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21601</ArticleId></ArticleIdList></Reference><Reference><Citation>Su D, Alshehri K, Pagan JA (2022) Income inequality and the disease burden of COVID-19: survival analysis of data from 74 countries. Prev Med Rep 27:101828</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2022.101828</ArticleId><ArticleId IdType="pubmed">35581989</ArticleId><ArticleId IdType="pmc">9101697</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor OG, Brzozowski JS, Skelding KA (2019) Glioblastoma Multiforme: an overview of emerging therapeutic targets. Front Oncol. ; 9: 963. 2019</Citation></Reference><Reference><Citation>Reiner AS, Lobaugh SM, Gonen S, Diamond EL, Panageas KS (2022) A population-based study of treatment and survival in older glioma patients. JNCI Cancer Spectr 6:pkac010</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jncics/pkac010</ArticleId><ArticleId IdType="pubmed">35699501</ArticleId><ArticleId IdType="pmc">8882385</ArticleId></ArticleIdList></Reference><Reference><Citation>Senders JT, Muskens IS, Schnoor R, Karhade AV, Cote DJ, Smith TR et al (2017) Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results. Acta Neurochir 159:151–167</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00701-016-3028-5</ArticleId><ArticleId IdType="pubmed">27878374</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoo M, Horan J, Gilmartin B, Nolan D, Corr P, MacNally S et al (2021) The provision of neuro-oncology and glioma neurosurgery during the SARS-CoV-2 pandemic: a single national tertiary centre experience. Ir J Med Sci (1971-) 190:905–911</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-020-02429-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen J, Qi X, Lyon KA, Liang B, Wang X, Feng D et al (2020) Lessons from China when performing neurosurgical procedures during the coronavirus disease 2019 (COVID-19) pandemic. World Neurosurg 138:e955–e60</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2020.04.140</ArticleId><ArticleId IdType="pubmed">32344132</ArticleId><ArticleId IdType="pmc">7194527</ArticleId></ArticleIdList></Reference><Reference><Citation>Che W, Wang Y, Wang X, Lyu JJCM (2022) Midlife brain metastases in the United States: is male at risk? Cancer Med 11:1202–1216</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.4499</ArticleId><ArticleId IdType="pubmed">35019232</ArticleId><ArticleId IdType="pmc">8855893</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>